Stockpolly
Search
Delisting risk
VRAX · NASDAQ · Biotechnology

Virax Biolabs Group (VRAX)

Develops T-cell immune profiling for post-infection syndromes and sells research-use immune reagents.

$2.54
Pre-market−0.02 (−0.78%)
At close$2.56(−1.54%)
Watchlist

In millions of USD, except per-share figures

In millionsQ2 FY21Sep 2020Q4 FY21Mar 2021Q2 FY22Sep 2021Q4 FY22Mar 2022Q2 FY23Sep 2022Q4 FY23Mar 2023Q2 FY24Sep 2023Q4 FY24Mar 2024Q2 FY25Sep 2024Q4 FY25Mar 2025Q2 FY26Sep 2025Q4 FY26Mar 2026
Revenue00000—000000
Cost of revenue00000—000000
Gross profit00000—000000
001114343326
Research & development000000011114
000114222213
Selling & marketing000000000000
General & administrative000114222203
Other expenses000100000000
Operating income00−1−1−1−4−3−4−3−3−3−6
000000000000
Interest income000000000000
Interest expense00000—000000
Other non-operating income00000000000−1
Income before tax00−1−1−1−4−3−4−3−3−3−6
Income tax expense00000000000−1
Net income from continuing operations00−1−1−1−4−3−4−3−3−2−5
Net income00−1−1−1−4−3−4−3−3−2−5
EPS, basic−$7.50−$6.75−$12.25−$25.50−$31.00−$64.50−$41.00−$42.75−$22.25−$19.00−$12.25−$12.64
EPS, diluted−$7.50−$6.75−$12.25−$25.50−$31.00−$64.50−$41.00−$42.75−$22.25−$19.00−$12.25−$12.64
Weighted average shares, basic000000000000
Weighted average shares, diluted000000000000
EBITDA000−100−3−4−3−3−2−6
Depreciation & amortization001114000000
EBIT00−1−1−1−4−3−4−3−3−3−6